Baikexing biological: Started clinical trials of intranasal influenza live attenuated vaccine for individuals aged 18-59 years old, and began subject enrollment work.

On August 25, according to Bacillus Bio, recently, Bacillus Bio successfully held a launch meeting for the clinical trial project evaluating the protective efficacy and safety of nasal spray flu attenuated live vaccine in the 18-59 year old population at the Hangzhou Disease Prevention and Control Center in Zhejiang province. The clinical research expanding the eligible population for the nasal spray flu attenuated live vaccine officially began in Hangzhou with the enrollment of participants on August 25.